Access count of this item: 844

Files in This Item:
File Description SizeFormat 
56_203.pdf625.11 kBAdobe PDFView/Open
Title: ホルモン抵抗性前立腺癌に対する低用量Docetaxel, Estramustine, Dexamethasone 併用療法の検討
Other Titles: Low-Dose Docetaxel, Estramustine and Dexamethasone Combination Chemotherapy for Hormone-Refractory Prostate Cancer
Authors: 小林, 一樹  KAKEN_name
横西, 哲広  KAKEN_name
伊藤, 悠亮  KAKEN_name
松本, 達也  KAKEN_name
梅本, 晋  KAKEN_name
逢坂, 公人  KAKEN_name
中村, 昌史  KAKEN_name
小貫, 竜昭  KAKEN_name
小宮, 敦  KAKEN_name
大古, 美治  KAKEN_name
酒井, 直樹  KAKEN_name
野口, 純男  KAKEN_name
岸, 洋一  KAKEN_name
横溝, 由美子  KAKEN_name
河合, 正記  KAKEN_name
岡島, 和登  KAKEN_name
田尻, 雄大  KAKEN_name
藤川, 敦  KAKEN_name
太田, 純一  KAKEN_name
湯村, 寧  KAKEN_name
森山, 正敏  KAKEN_name
Author's alias: Kobayashi, Kazuki
Yokonishi, Tetsuhiro
Ito, Yusuke
Matsumoto, Tatsuya
Umemoto, Susumu
Osaka, Kimito
Nakamura, Masafumi
Onuki, Tatsuaki
Komiya, Atsushi
Ohgo, Yoshiharu
Sakai, Naoki
Noguchi, Sumio
Kishi, Hiroichi
Yokomizo, Yumiko
Kawai, Masaki
Okajima, Kazuto
Tajiri, Takehiro
Fujikawa, Atsushi
Ohta, Junichi
Yumura, Yasushi
Moriyama, Masatoshi
Keywords: Hormone-refractory prostate cancer
Issue Date: Apr-2010
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 56
Issue: 4
Start page: 203
End page: 207
Abstract: The objective of this study was to evaluate the efficacy and safety of low-dose docetaxel, estramustine and dexamethasone combination chemotherapy in patients with hormone-refractory prostate cancer (HRPC). Sixty-nine patients with HRPC were enrolled. Docetaxel was given at a dose of 25 mg/m2 on days 1 and 8 every 3 weeks, oral estramustine 280 mg twice daily on days 1 to 3 and 8 to 10, and oral dexamethasone 1mg daily throughout the course. Cycles were repeated every 21 days. Treatment was continued until disease progression or excessive toxicity. Patients were evaluated for response and toxicity. Patients received a median of eleven cycles (range : 1-25). Prostatic-specific antigen (PSA) was decreased greater than 50% in 53 (77%) out of 69 patients and median duration of PSA response was 10.2 months. Median time to progression and overall survival 10.2 and 24 months, respectively. Grade 1-2 fatigue was the most common toxicity observed in 10 (15%) patients. Grade 3-4 toxicities were observed in five (7%) patients (2 thrombosis, 2 bilirubin elevation, and 1 aspartate transaminase/alanine transaminase elevation). Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy is an effective and well tolerated treatment for Japanese HRPC patients.
Rights: 許諾条件により本文は2011-05-01に公開
PubMed ID: 20448443
Appears in Collections:Vol.56 No.4

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.